

Lorbrena® (Iorlatinib) – Expanded indication

- On March 3, 2021, <u>Pfizer announced</u> the FDA approval of <u>Lorbrena (lorlatinib)</u>, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
 - Previously, Lorbrena was approved for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on: Xalkori® (crizotinib) and at least one other ALK inhibitor for metastatic disease; or Alecensa® (alectinib) as the first ALK inhibitor therapy for metastatic disease; or Zykadia® (ceritinib) as the first ALK inhibitor therapy for metastatic disease.
 - The FDA also converted the accelerated approval for this indication to full approval.
- This approval expands the indication to include first-line treatment of patients with NSCLC.
- The approval of Lorbrena for the expanded indication was based on the CROWN study, an openlabel, randomized, active-controlled trial in 296 patients with ALK-positive NSCLC who had not received prior systemic therapy for metastatic disease. Patients were randomized to receive Lorbrena or Xalkori. The major efficacy outcome measure was progression-free survival (PFS). Additional efficacy outcome measures were overall survival (OS), overall response rate (ORR), and duration of response (DOR).
 - Median PFS was not estimable for Lorbrena vs. 9.3 months for Xalkori (hazard ratio 0.28, 95% CI: 0.19, 0.41; p < 0.0001).
 - The ORR was 76% (95% Cl: 68, 83) for Lorbrena vs. 58% (95% Cl: 49, 66) for Xalkori.
 - The median DOR was not estimable (range: 0.9, 31.3) for Lorbrena vs. 11 months (range: 1.1, 27.5) for Xalkori.
 - At the data cutoff point OS data was not mature.
- The recommended dosage of Lorbrena is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.



optumrx.com

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.